We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Glucose Levels May Predict Pneumonia Death Risk

By LabMedica International staff writers
Posted on 18 Jun 2012
Print article
Nondiabetic patients who have high blood glucose on admission for community-acquired pneumonia (CAP) are at significantly elevated risk for death and may benefit from intensified care.

There is a strong association between diabetes and cardiovascular disease that contributes to overall mortality from CAP and infection and acute hyperglycemia, related illnesses.

At the University Hospital of Saarland (Homburg, Germany) scientists carried out a prospective multicenter study on 6,891 patients from 12 clinical centers. The study began in July 2002, and was analyzed in December 2009. The mean age of participants was 59.8 ±18.5 years and 3,805 (55.2%) were men. Overall, 324 (4.7%) participants died within 28 days, 514 (7.5%) within 90 days, and 648 (9.4%) within 180 days. Overall mortality on days 28, 90, and 180 was significantly higher in participants with diabetes than without diabetes.

Higher serum glucose levels were associated with increased mortality in all patients. Mortality within 90 days increased in a stepwise manner in those with glucose concentrations of 108-197 mg/dL, 198-251 mg/dL, and equal or greater than 252 mg/dL when compared with patients with normal serum glucose concentrations of 72-107 mg/dL. Nondiabetics with normal blood glucose levels had the lowest 90-day mortality rate of 3%, while those with hyperglycemia had a mortality rate of 10%, and patients with diabetes had the highest death rate at 14%, irrespective of glucose levels on admission.

The authors concluded that patients with increased serum glucose levels or diabetes at the time of CAP was diagnosed were at significantly increased risk of death from the disease. Oral glucose tolerance test and close glucose monitoring after discharge are necessary to diagnose overt diabetes and to prevent subacute or long-term complications. The study was published on May 29, 2012, in the British Medical Journal (BMJ).

Related Links:
University Hospital of Saarland


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.